PharmaFocus Today – Page 127 – media

“Gastrointestinal Endoscopic Surgical Instrument Control Equipment” is approved for market launch

Recently, the National Medical Products Administration approved the registration application for the innovative product “Gastrointestinal Endoscopic Surgical Instrument Control Equipment” of Shenzhen Robb Medical Technology Co., Ltd. (hereinafter referred to as Robb Medical). Fill the domestic gap Founded in 2015, Robb Medical is a medical robot research and development enterprise that has entered the industrialization stage. Since its establishment, it has been committed to the technological research and development of flexible digestive endoscopic surgical robots, and is currently the earliest surgical robot company in the world to enter the industrialization stage in this field. After years of development, Robb Medical has become a hub for technology and talent in the field of medical robotics. It has accumulated certain technologies in the manufacturing of rehabilitation robots, flexible robotic arms, parallel surgical robot design and control, force feedback, machine vision, automatic surgery, and has taken the lead in using these technologies in ...
- Source: drugdu
- 304
- March 18, 2025
Levosalbutamol Hydrochloride Nebulized Inhalation Solution Obtains Drug Registration Certificate

On March 14, Luoxin Pharmaceuticals issued an announcement stating that its subsidiary Luoxin Anruovita Pharmaceuticals (Chengdu) Co., Ltd. received the “Drug Registration Certificate” for Levosalbutamol Hydrochloride Nebulized Inhalation Solution approved and issued by the State Drug Administration. Levosalbutamol is a β2-adrenergic receptor agonist that can relax all airway smooth muscles from the trachea to the terminal bronchioles. Levosalbutamol Hydrochloride Nebulized Inhalation Solution is suitable for the treatment or prevention of bronchospasm caused by reversible airway obstructive diseases in adults and children over 6 years old. The original developer of Levosalbutamol Hydrochloride Nebulized Inhalation Solution was Sepracor Inc. of the United States. It was launched in the United States in 1999 under the trade name: XOPENEX. The original formulation has not yet been imported into China. The company’s salbutamol hydrochloride nebulized inhalation solution has obtained a drug registration certificate according to the new registration classification of chemical drugs, Class 3, and ...
- Source: drugdu
- 257
- March 18, 2025
Obtained the Drug Registration Certificate for Taijilidine Fumarate Injection

On March 16, Hengrui Medicine (600276.SH) announced that the company received the “Drug Registration Certificate” for Taijilidine Fumarate Injection approved and issued by the National Medical Products Administration, approving the company’s independently developed Class 1 innovative drug Taijilidine Fumarate Injection to add new indications and merge and revise the instructions. The indication is for the treatment of moderate to severe postoperative pain. The drug is a μ opioid receptor-biased small molecule agonist, which was approved for marketing in China in January 2024. It is suitable for moderate to severe pain after abdominal surgery and is China’s first independently developed Class 1 opioid analgesic innovative drug. As of now, the cumulative R&D investment in related projects is approximately RMB 197.91 million. https://finance.eastmoney.com/a/202503163346884091.html
- Source: drugdu
- 246
- March 18, 2025
Expected to Significantly Reduce Losses in 2024

AIM Vaccine announced on the Hong Kong Stock Exchange in the morning of March 17 that it expects to significantly reduce losses in performance. It is expected to record unaudited revenue of between 1.25 billion and 1.3 billion during the reporting period, an increase of 60 million to 110 million from the previous year’s revenue of 1.19 billion, an increase of 5% to 9%, and an unaudited net loss of between 250 million and 290 million yuan, a significant reduction of 1.66 billion to 1.7 billion from the previous year’s net loss of 1.95 billion yuan, a reduction of 85% to 87%. The board of directors initially believes that the increase in revenue is mainly due to the increase in the company’s hepatitis B vaccine revenue, and the reduction in comprehensive net losses is mainly due to the reduction in the amount of large asset impairment losses and the increase in ...
- Source: drugdu
- 266
- March 18, 2025
China’s first and the world’s second IGF-1R antibody drug approved for marketing

Good news for patients with thyroid eye disease! Tetuinumab N01 injection (trade name “Synbimin”), the first IGF-1R antibody drug in China and the second in the world developed by Innovent Biologics, was approved for marketing by the National Medical Products Administration (NMPA) on March 14 for the treatment of thyroid eye disease (TED). “The protracted course of thyroid eye disease seriously affects the patient’s visual function and appearance, and can bring a heavy psychological burden to the patient. At present, glucocorticoids are the first choice for the treatment of thyroid eye disease in China, but their efficacy in treating exophthalmos is limited and has obvious adverse reactions. Biologics targeting IGF-1R can significantly improve the symptoms of exophthalmos in patients with thyroid eye disease and improve their quality of life, and are bound to play an important role in the treatment of thyroid eye disease.” Professor Fan Xianqun, an academician of ...
- Source: drugdu
- 416
- March 18, 2025
Breaking the Waves with “Dao, Fa, and Shu”

In the vast sea of stars in the biopharmaceutical industry, Novartis is like a giant ship sailing through the wind and waves, with technological innovation as the sail and strategic determination as the anchor, opening up a unique route. Recently, a reporter from Shanghai Securities News walked into the headquarters and R&D center of Nuotai Biotechnology, and through a conversation with the company’s chairman Tong Ziquan, explored the growth logic of this science and technology innovation board enterprise. In recent years, Novartis has made significant achievements in the fields of peptides, oligonucleotides, and small molecule pharmaceuticals. The company has overcome the challenge of large-scale production of long-chain peptides, and with the increasing volume of products such as semaglutide, its demand for peptide raw material procurement will significantly increase in 2024. At the same time, the company has been forward-looking in the field of oligonucleotides since 2022 and has rapidly formed ...
- Source: drugdu
- 289
- March 17, 2025
World First! One innovative medical device approved for market launch

Recently, the National Medical Products Administration approved the registration application for the innovative product “Transcatheter Tricuspid Ring Forming System” of Shanghai Huihe Medical Technology Co., Ltd. (hereinafter referred to as Huihe Medical). Rich pipelines, multiple pioneering products launched Huihe Medical was founded in 2019 and is a world leading cardiovascular intervention platform company with independent innovation capabilities. At present, Huihe Medical has four major platforms including delivery systems, clinical medical technology, precision manufacturing, and global marketing, all of which have industry-leading advantages. We have independently developed and world leading related products in the fields of heart valve intervention, vascular intervention, electrophysiological intervention, drug delivery intervention, and intelligent intervention. The K-Clip approved for listing this time ® The transcatheter tricuspid annuloplasty system is the world’s first transcatheter tricuspid annulus repair system independently developed by Huihe Medical, filling the gap in the field of tricuspid valve intervention in China and used to ...
- Source: drugdu
- 387
- March 17, 2025
Over 27.6 billion! The rise of Chinese medicine giants under the “China Resources” brand

According to the announcement, China Resources Sanjiu achieved a total revenue of approximately 27.617 billion yuan in 2024, a year-on-year increase of 11.63%; The net profit attributable to shareholders of the listed company is approximately 3.368 billion yuan, a year-on-year increase of 18.05. Specifically, in terms of quarterly performance, from the first quarter to the fourth quarter of 2024, China Resources Sanjiu achieved operating revenues of 7.294 billion yuan, 6.812 billion yuan, 5.634 billion yuan, and 7.876 billion yuan, respectively, with net profits of 1.364 billion yuan, 1.034 billion yuan, 561 million yuan, and 408 million yuan. In the fourth quarter, China Resources Sanjiu’s revenue increased by about 28.5% year-on-year, while its net profit decreased by 10.3% year-on-year. Behind the numbers lies not only the growth trajectory of a company, but also the wave of the times in China’s pharmaceutical industry driven by policy guidance, market changes, and innovation. 01. ...
- Source: drugdu
- 329
- March 17, 2025
How Can AI Empower Medical B2B Trade? A Must-Try Industry Assistant

I. How Can AI Empower Medical B2B Trade? In global pharmaceutical and medical device B2B trade, challenges such as information opacity, complex compliance requirements, unpredictable market trends, and cross-border trade barriers have long troubled industry users. Businesses often invest significant time and effort in researching regulations, analyzing market data, and assessing procurement risks—precisely where AI can play a vital role. The launch of Drugdu AI marks a breakthrough in the application of AI in the pharmaceutical B2B sector. Developed by Drugdu.com, this intelligent industry assistant is powered by DeepSeek AI technology, designed to provide users with precise industry insights, regulatory guidance, and market trend analysis, ultimately optimizing procurement and supply chain decisions. But is Drugdu AI truly practical? What scenarios does it apply to? How accurate are its AI-generated responses? We conducted in-depth testing and summarized some practical usage recommendations for industry users. II. Drugdu AI Hands-on Experience: Core Feature Breakdown We ...
- Source: drugdu
- 606
- March 17, 2025
Utilizing stem cells to create a new type of vascular graft, the ‘universal life pipeline’, to promote progress in related surgeries

In a study published in the latest issue of Cell Reports Medicine, scientists from the National Primate Research Center in Wisconsin and the University of Wisconsin Madison demonstrated a “universal life pipeline” – a novel small-diameter vascular graft developed using stem cell-derived arterial endothelial cells (AECs). This achievement is of great significance for advancing research in biotechnology and vascular surgery. Blood vessels are known as the “life vessels” of the human body. Currently, synthetic vascular grafts have been widely used for repairing large blood vessels, but for small diameter vessels such as those used in coronary artery bypass surgery, the existing options are very limited. The usual method is to extract blood vessels from other parts of the patient’s body, but this is not only highly invasive, but also limited by the number and quality of available blood vessels, especially when the patient has comorbidities. Another method is to use ...
- Source: drugdu
- 273
- March 14, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.